Literature DB >> 35592437

Agonist-Dependent Coupling of the Promiscuous Adenosine A2B Receptor to Gα Protein Subunits.

Jan Hendrik Voss1, Andhika B Mahardhika1,2, Asuka Inoue3, Christa E Müller1,2.   

Abstract

The adenosine A2B receptor (A2BAR) belongs to the rhodopsin-like G protein-coupled receptor (GPCR) family. It is upregulated under hypoxic conditions, in inflammation and cancer. Previous studies indicated the coupling of the A2BAR to different G proteins, mainly Gs, but in some cases Gq/11 or Gi, depending on the cell type. We have now utilized novel technologies, (i) heterologous expression of individual members of the Gαq/11 protein family (Gαq, Gα11, Gα14, and Gα15) in Gαq/11 knockout cells, and (ii) the TRUPATH platform, allowing the direct observation of Gα protein activation for each of the Gα subunits by bioluminescence resonance energy transfer (BRET) measurements. Three structurally diverse A2BAR agonists were studied: the cognate agonist adenosine, its metabolically stable analog NECA, and the non-nucleosidic partial agonist BAY 60-6583. Adenosine and NECA activated most members of all four Gα protein families (Gαs, Gαq/11, Gαi, and Gα12/13). Significant differences in potencies and efficacies were observed; the highest efficacies were determined at the Gα15, Gαs, and Gα12 proteins, and for NECA additionally at the Gαi2 protein. In contrast, the partial agonist BAY 60-6583 only activated Gα15, Gαs, and Gα12 proteins. Adenosine deaminase, an allosteric modulator of ARs, selectively increased the potency and efficacy of NECA and BAY 60-6583 at the Gα15 protein, while it had no effect or decreased efficacy at the other Gα proteins. We conclude that the A2BAR is preferably coupled to the Gα15, Gαs, and Gα12 proteins. Upon upregulation of receptor or Gα protein expression, coupling to further Gα proteins likely occurs. Importantly, different agonists can display different activation profiles.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35592437      PMCID: PMC9112290          DOI: 10.1021/acsptsci.2c00020

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  59 in total

Review 1.  A2B adenosine receptor antagonists: recent developments.

Authors:  Barbara Cacciari; Giorgia Pastorin; Chiara Bolcato; Giampiero Spalluto; Magdalena Bacilieri; Stefano Moro
Journal:  Mini Rev Med Chem       Date:  2005-12       Impact factor: 3.862

2.  Illuminating G-Protein-Coupling Selectivity of GPCRs.

Authors:  Asuka Inoue; Francesco Raimondi; Francois Marie Ngako Kadji; Gurdeep Singh; Takayuki Kishi; Akiharu Uwamizu; Yuki Ono; Yuji Shinjo; Satoru Ishida; Nadia Arang; Kouki Kawakami; J Silvio Gutkind; Junken Aoki; Robert B Russell
Journal:  Cell       Date:  2019-05-31       Impact factor: 41.582

3.  A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions.

Authors:  Céline Laschet; Nadine Dupuis; Julien Hanson
Journal:  J Biol Chem       Date:  2018-12-28       Impact factor: 5.157

4.  On the G protein-coupling selectivity of the native A2B adenosine receptor.

Authors:  Zhan-Guo Gao; Asuka Inoue; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2017-12-07       Impact factor: 5.858

5.  SIGNAL TRANSDUCTION. Structural basis for nucleotide exchange in heterotrimeric G proteins.

Authors:  Ron O Dror; Thomas J Mildorf; Daniel Hilger; Aashish Manglik; David W Borhani; Daniel H Arlow; Ansgar Philippsen; Nicolas Villanueva; Zhongyu Yang; Michael T Lerch; Wayne L Hubbell; Brian K Kobilka; Roger K Sunahara; David E Shaw
Journal:  Science       Date:  2015-06-19       Impact factor: 47.728

Review 6.  Adenosine and the treatment of supraventricular tachycardia.

Authors:  A C Rankin; R Brooks; J N Ruskin; B A McGovern
Journal:  Am J Med       Date:  1992-06       Impact factor: 4.965

7.  TGFα shedding assay: an accurate and versatile method for detecting GPCR activation.

Authors:  Asuka Inoue; Jun Ishiguro; Hajime Kitamura; Naoaki Arima; Michiyo Okutani; Akira Shuto; Shigeki Higashiyama; Tomohiko Ohwada; Hiroyuki Arai; Kumiko Makide; Junken Aoki
Journal:  Nat Methods       Date:  2012-09-16       Impact factor: 28.547

8.  An experimental strategy to probe Gq contribution to signal transduction in living cells.

Authors:  Julian Patt; Judith Alenfelder; Eva Marie Pfeil; Jan Hendrik Voss; Nicole Merten; Funda Eryilmaz; Nina Heycke; Uli Rick; Asuka Inoue; Stefan Kehraus; Xavier Deupi; Christa E Müller; Gabriele M König; Max Crüsemann; Evi Kostenis
Journal:  J Biol Chem       Date:  2021-02-24       Impact factor: 5.157

Review 9.  The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease.

Authors:  Jiang-Fan Chen; Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2020-03-31       Impact factor: 3.765

Review 10.  Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.

Authors:  François Ghiringhelli; Mélanie Bruchard; Fanny Chalmin; Cédric Rébé
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more
  2 in total

1.  Transmembrane Domain 3 Is a Transplantable Pharmacophore in the Photodynamic Activation of Cholecystokinin 1 Receptor.

Authors:  Yuan Li; Zong Jie Cui
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-08

2.  Irreversible Antagonists for the Adenosine A2B Receptor.

Authors:  Ahmed Temirak; Jonathan G Schlegel; Jan H Voss; Victoria J Vaaßen; Christin Vielmuth; Tobias Claff; Christa E Müller
Journal:  Molecules       Date:  2022-06-13       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.